- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and sponsored by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham
- Elraglusib will be assessed in combination with dinutuximab beta plus chemotherapy in patients with relapsed and refractory neuroblastoma
- Complete response in neuroblastoma patient achieved in Phase 1 study of elraglusib in refractory pediatric cancers
DELRAY BEACH, Fla., June 9, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the EV Battery Market is projected to reach USD 168.95 billion by 2035, from USD...
BEIJING, June 9, 2026 /PRNewswire/ -- Uxin Limited ("Uxin" or the "Company") (Nasdaq: UXIN), China's leading used car retailer, today announced that it will...
VANCOUVER, BC, June 9, 2026 /CNW/ - Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) ("Trilogy Metals", "Trilogy" or the "Company") announced today that field...
MBRYONICS Unveils STARLIGHT, The World's First 25G/100G/400G/800G Bi-Directional Coherent Optical Transceiver for Ultra High Speed Space LinksGALWAY, Ireland, June 9, 2026 /PRNewswire/ -- MBRYONICS,...
ISTANBUL, June 9, 2026 /PRNewswire/ -- HIKSEMI, a globally trusted provider of storage solutions, successfully concluded its Turkey Storage Solutions Technology Summit today at the...
Updated page highlights BC Engine's operating model, live platform data and ecosystem contributors, with BETBY becoming the latest partner in the $BC rewards model.BELIZE...